European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, Myeloma29 April 2025
Register now to join the webinar ‘How do different countries make decisions on reimbursing new medicines?’Access, MPE6 March 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, News3 March 2025
The European Commission approves isatuximab + VRd combination therapy for newly diagnosed, transplant ineligible myeloma patientsAccess, Myeloma, News24 January 2025
Myeloma and AL amyloidosis ASH 2024 previewAccess, AL amyloidosis, CAR-T, MPE, Myeloma29 November 2024
EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patientsAccess, Myeloma, News20 November 2024
MPE comments on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union levelAccess, News29 October 2024
During European Myeloma Day, MPE highlights the importance of improving access to clinical trialsAccess, MPE, Myeloma27 September 2024
EMA recommends a new indication for daratumumab in adult patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantAccess, Myeloma26 September 2024
